Drug firm Lupin is looking to launch ten products in the Japanese market through its arm Kyowa Pharmaceutical in the next fiscal as it eyes to cash in on the recent Indo-Japan trade pact that opened the doors for the country's generic medicines there. With the introduction of the ten new products, Lupin expects revenues from the Japanese market to grow by 20-25% in the next fiscal.
The company will be launching ten products in the Japanese market in different therapeutic areas, including central nervous system (CNS), cardiology, diabetes and gynecology in the next fiscal. The company, which operates in Japan through its subsidiary Kyowa Pharmaceuticals Industry, will address a target market size of close to$ 3 billion through these new launches. Kyowa reported sales of 10.4 billion yen (nearly Rs 575 crore) in Japan in 2009-10. The company is expecting to close the current fiscal at 11.6 billion yen (about Rs 640 crore).
Kyowa grew by 16% clocking net sales of Rs 172.7 crore in the third quarter FY11 as against Rs 148.9 crore in the same period last fiscal, contributing 12% to Lupin's consolidated revenues. In FY 2010, Japan contributed 11-12% to Lupin's total revenues of Rs 4,740.5 crore.crackcrack
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |